Yahoo · Nov 4, 2026
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +15.79% and +43.95%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

